Literature DB >> 28579407

Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing.

Santiago Munné1, Joshua Blazek2, Michael Large2, Pedro A Martinez-Ortiz3, Haley Nisson4, Emmeline Liu4, Nicoletta Tarozzi5, Andrea Borini5, Amie Becker6, John Zhang6, Susan Maxwell7, James Grifo7, Dhruti Babariya8, Dagan Wells8, Elpida Fragouli8.   

Abstract

OBJECTIVE: To determine the pregnancy outcome potential of mosaic embryos, detected by means of preimplantation genetic screening (PGS) with the use of next-generation sequencing (NGS).
DESIGN: Retrospective study.
SETTING: Genetics laboratories. PATIENT(S): PGS cycles during which either mosaic or euploid embryos were replaced. INTERVENTION(S): Blastocysts were biopsied and processed with the use of NGS, followed by frozen embryo transfer. Trophectoderm (TE) biopsies were classified as mosaic if they had 20%-80% abnormal cells. MAIN OUTCOME MEASURE(S): Implantation, miscarriage rates, and ongoing implantation rates (OIRs) were compared between euploid and types of mosaic blastocysts. RESULT(S): Complex mosaic embryos had a significantly lower OIR (10%) than aneuploidy mosaic (50%), double aneuploidy mosaic (45%), and segmental mosaic (41%). There was a tendency for mosaics with 40%-80% abnormal cells to have a lower OIR than those with <40% (22% vs. 56%). However, few embryos (n = 34) with a mosaic error in 40%-80% of the TE sample were replaced. There was no difference between monosomic and trisomic mosaics or between entire chromosome mosaicism or segmental mosaicism. Implantation rates were significantly higher (70% vs. 53%), miscarriage rates lower (10% vs. 25%), and OIRs higher (63% vs. 40%) after euploid embryo transfer than after mosaic embryo transfer. CONCLUSION(S): Forty-one percent of mosaic embryos produced an ongoing implantation. Complex mosaic blastocysts had a lower OIR than other mosaics. Mosaic monosomies performed as well as mosaic trisomies and mosaic segmental aneuploidies. The results suggest that embryos with >40% abnormal cells and those with multiple mosaic abnormalities (chaotic mosaics) are likely to have lower OIRs and should be given low transfer priority.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mosaicism; PGD/PGS; next-generation sequencing; pregnancy outcome

Mesh:

Year:  2017        PMID: 28579407     DOI: 10.1016/j.fertnstert.2017.05.002

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  56 in total

1.  Cumulus-corona gene expression analysis combined with morphological embryo scoring in single embryo transfer cycles increases live birth after fresh transfer and decreases time to pregnancy.

Authors:  T Adriaenssens; I Van Vaerenbergh; W Coucke; I Segers; G Verheyen; E Anckaert; M De Vos; J Smitz
Journal:  J Assist Reprod Genet       Date:  2019-01-09       Impact factor: 3.412

2.  Worldwide live births following the transfer of chromosomally "Abnormal" embryos after PGT/A: results of a worldwide web-based survey.

Authors:  Pasquale Patrizio; Gon Shoham; Zeev Shoham; Milton Leong; David H Barad; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2019-06-24       Impact factor: 3.412

3.  Less-invasive chromosome screening of embryos and embryo assessment by genetic studies of DNA in embryo culture medium.

Authors:  Jing Zhang; Hong Xia; Haixia Chen; Chenxi Yao; Lizhen Feng; Xueru Song; Xiaohong Bai
Journal:  J Assist Reprod Genet       Date:  2019-11-15       Impact factor: 3.412

4.  The reproducibility of trophectoderm biopsies in euploid, aneuploid, and mosaic embryos using independently verified next-generation sequencing (NGS): a pilot study.

Authors:  Nidhee M Sachdev; David H McCulloh; Yael Kramer; David Keefe; James A Grifo
Journal:  J Assist Reprod Genet       Date:  2020-02-28       Impact factor: 3.412

Review 5.  The mechanisms and clinical application of mosaicism in preimplantation embryos.

Authors:  Xinyuan Li; Yan Hao; Nagwa Elshewy; Xiaoqian Zhu; Zhiguo Zhang; Ping Zhou
Journal:  J Assist Reprod Genet       Date:  2019-12-14       Impact factor: 3.412

6.  New perspectives with the use of noninvasive chromosome screening (NICS) in ART.

Authors:  José G Franco
Journal:  JBRA Assist Reprod       Date:  2019-10-14

7.  Healthy live births from transfer of low-mosaicism embryos after preimplantation genetic testing for aneuploidy.

Authors:  Chun-I Lee; En-Hui Cheng; Maw-Sheng Lee; Pin-Yao Lin; Yi-Chun Chen; Chien-Hong Chen; Lii-Shung Huang; Chun-Chia Huang; Tsung-Hsien Lee
Journal:  J Assist Reprod Genet       Date:  2020-07-04       Impact factor: 3.412

8.  In vitro fertilization does not increase the incidence of de novo copy number alterations in fetal and placental lineages.

Authors:  Masoud Zamani Esteki; Triin Viltrop; Olga Tšuiko; Airi Tiirats; Mariann Koel; Margit Nõukas; Olga Žilina; Katre Teearu; Heidi Marjonen; Hanna Kahila; Jeroen Meekels; Viveca Söderström-Anttila; Anne-Maria Suikkari; Aila Tiitinen; Reedik Mägi; Sulev Kõks; Nina Kaminen-Ahola; Ants Kurg; Thierry Voet; Joris Robert Vermeesch; Andres Salumets
Journal:  Nat Med       Date:  2019-11-04       Impact factor: 53.440

9.  Single best euploid versus single best unknown-ploidy blastocyst frozen embryo transfers: a randomized controlled trial.

Authors:  Kemal Ozgur; Murat Berkkanoglu; Hasan Bulut; Gonul Didem Akay Yoruk; Nevrah Nal Candurmaz; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2019-01-07       Impact factor: 3.412

10.  Incidence, Origin, and Predictive Model for the Detection and Clinical Management of Segmental Aneuploidies in Human Embryos.

Authors:  Laura Girardi; Munevver Serdarogullari; Cristina Patassini; Maurizio Poli; Marco Fabiani; Silvia Caroselli; Onder Coban; Necati Findikli; Fazilet Kubra Boynukalin; Mustafa Bahceci; Rupali Chopra; Rita Canipari; Danilo Cimadomo; Laura Rienzi; Filippo Ubaldi; Eva Hoffmann; Carmen Rubio; Carlos Simon; Antonio Capalbo
Journal:  Am J Hum Genet       Date:  2020-03-26       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.